Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Confirmatory Study of K-877 Extended Release vs Immediate Release in Dyslipidemia with High Triglycerides
jRCT2051200128Phase 3Completed
- Sponsor
- Kowa Company, Ltd.
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pemafibrate in dyslipidemia and hypertriglyceridemia (3 arms), sponsored by Kowa Company, Ltd. Primary endpoints: Percent change from baseline in fasting serum triglycerides at 4 weeks, Percent change from baseline in fasting serum triglycerides at 8 weeks and 1 more. Started Mar 2021; status: completed.
02
Drugs
pemafibrate
03
Conditions
dyslipidemiahypertriglyceridemia
Beyond the preview
Go deeper on jRCT2051200128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051200128.